Get the Stockscreener App
40.88
1.23%
-0.51
Exelixis Inc stock is traded at $40.88, with a volume of 2.57M.
It is down -1.23% in the last 24 hours and down -6.22% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$41.39
Open:
$41.66
24h Volume:
2.57M
Relative Volume:
0.94
Market Cap:
$10.96B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
23.10
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
-7.84%
1M Performance:
-6.22%
6M Performance:
-2.15%
1Y Performance:
+16.20%
1-Day Range:
$40.66
$41.79
1-Week Range:
$40.66
$44.59
52-Week Range:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
40.88 | 11.10B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis Inc Stock Analysis and ForecastMarket Depth Overview & Small Budget Big Profits - earlytimes.in
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) - The Globe and Mail
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Exelixis (EXEL) Receives a Hold from RBC Capital - The Globe and Mail
Exelixis stock holds steady as Stifel maintains $43 price target By Investing.com - Investing.com Canada
EXEL to Host Research and Development Day in December - GuruFocus
Analyst Upgrade: Can Exelixis Inc EX9 stock stage a strong rebound this quarterSell Signal & Daily Profit Focused Stock Screening - moha.gov.vn
(EXEL) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
It's A Story Of Risk Vs Reward With Exelixis, Inc. (NASDAQ:EXEL) - 富途牛牛
Exelixis (EX9.DE) Stock Analysis: Navigating Challenges with Resilience - Meyka
Earnings Recap: Can Exelixis Inc stock hit analyst price targetsQuarterly Portfolio Review & Scalable Portfolio Growth Ideas - moha.gov.vn
Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates - sharewise.com
Exelixis Stock Presents a Complex Investment Narrative - AD HOC NEWS
Levels Update: How analysts revise price targets for Exelixis Inc EX9 stockJuly 2025 Movers & Verified Momentum Stock Ideas - moha.gov.vn
Exelixis shuttering Pennsylvania site, laying off 130 employees - MSN
Will Exelixis Inc. (EX9) stock outperform energy sector in 20252025 Trading Recap & Low Risk High Win Rate Picks - Newser
Will Exelixis Inc. stock attract more institutional investorsTrend Reversal & Reliable Entry Point Trade Alerts - Newser
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
How forex fluctuations impact Exelixis Inc. (EX9) stockRisk Management & Weekly Stock Performance Updates - Newser
Will Exelixis Inc. (EX9) stock profit from automation wave2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
Why Exelixis Inc. (EX9) stock appeals to dividend investorsTreasury Yields & AI Forecasted Stock Moves - Newser
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? - Yahoo Finance
Will Exelixis Inc. (EX9) stock rise with strong economyWeekly Stock Summary & Smart Money Movement Alerts - Newser
How Exelixis Inc. (EX9) stock compares with top peers2025 Market Overview & Safe Entry Momentum Stock Tips - Newser
Can Exelixis Inc. (EX9) stock beat analyst consensusWeekly Profit Analysis & Reliable Breakout Stock Forecasts - Newser
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
Exelixis (NASDAQ:EXEL) shareholders have earned a 39% CAGR over the last three years - Yahoo Finance
Vascular Endothelial Growth Factor Receptor (VEGFR) - openPR.com
Is Exelixis Inc. stock a buy for dividend growthWall Street Watch & Free Community Supported Trade Ideas - Newser
How Exelixis Inc. (EX9) stock trades under stagflationQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Will Exelixis Inc. (EX9) stock announce a stock split2025 Earnings Impact & Weekly Top Gainers Trade List - Newser
Can Exelixis Inc. (EX9) stock retain market dominanceRate Cut & Daily Risk Controlled Trade Plans - Newser
2 Under-the-Radar Stocks to Buy Heading Into 2026 - Finviz
2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
EXEL (Exelixis) Earnings Yield (Joel Greenblatt) % : 7.99% (As of Sep. 2025) - GuruFocus
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK
Here's Why Exelixis (EXEL) is a Strong Growth Stock - MSN
EXEL (Exelixis) Cash, Cash Equivalents, Marketable Securities : $989 Mil (As of Sep. 2025) - GuruFocus
EXEL (Exelixis) Total Assets : $2,824 Mil (As of Sep. 2025) - GuruFocus
Hedge Fund and Insider Trading News: Ray Dalio, Michael Burry, Marshall Wace, Exelixis Inc (EXEL), Monolithic Power Systems Inc (MPWR), and More - Insider Monkey
Exelixis (LTS:0IJO) FCF Yield % : 6.28 (As of Nov. 28, 2025) - GuruFocus
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners - MSN
How (EXEL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Aug Rallies: How Exelixis Inc. stock reacts to job market dataQuarterly Market Review & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Exelixis (EXEL) Director Invests $1.2 Million in Company Stock - GuruFocus
Dir Johnson Buys 27,532 ($1.2M) Of Exelixis Inc [EXEL] - TradingView
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):